nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is quite modest. We hope to hang with a couple of the short people, catch up on chores, and then scoot off to the JP Morgan health care zoo taking place next week (which means Pharmalittle will arrive each morning later than usual). And what about you? You could go shopping for winter sweaters, since this a good time of year to find a bargain on such items. You could stay in and curl up with a good book. Or simply dream about a trip to someplace warm. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …

Senator Chuck Grassley (R-Iowa), wants the Centers for Medicare and Medicaid Services to investigate whether two drugs, Dilaudid and Prilosec, were misclassified under the Medicaid Drug Rebate Program. Grassley, who pushed for an investigation into rebates paid by Mylan Pharmaceuticals for its EpiPen device, is concerned the government program may have overpaid for the medicines if these were not correctly classified.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy